Diverse expansion methods and automated platforms offer pathways to scalable CAR-T cell manufacturing
New manufacturing methods aim to scale CAR-T cell therapy production
This narrative review examines ex vivo T-cell expansion techniques for CAR-T therapy in B-cell malignancies and multiple myeloma. It identif…
New manufacturing technologies and automated platforms aim to overcome hurdles in scaling CAR-T cell therapy for patients with blood cancers…
CAR-T in solid tumors: 13% ORR, 63% DCR, lymphopenia most common AE
CAR-T Cell Therapy Shows Potential for Solid Tumor Treatment
This meta-analysis of 52 studies evaluated CAR-T cell therapy in 712 patients with solid tumors. Pooled overall response rate was 13% (95% C…
New data on CAR-T cell therapy shows promising response rates for solid tumors, though specific delivery methods impact safety and effective…
CAR-T cell therapy shows preliminary clinical activity in refractory neuroimmune diseases
CAR-T Cell Therapy Shows Early Activity in Neuroimmune Diseases
This narrative review synthesizes current evidence on CAR-T cell therapies targeting CD19, BCMA, or dual CD19/BCMA for neuroimmune diseases.…
New CAR-T cell therapies are showing early clinical activity for patients with rare and difficult to treat neuroimmune conditions.
B-cell targeted therapies show durable immune responses in pemphigus vulgaris and myasthenia gravis
New data shows how B-cell therapies treat autoimmune diseases
This systematic review of 24 clinical trials involving more than 3,500 participants evaluates B-cell targeted therapies for various autoimmu…
New research highlights how targeting specific immune cells can provide lasting relief for several different autoimmune conditions.
High CAR-HEMATOTOX scores correlate with increased ICAHT odds and worse survival in CAR T-cell therapy
New Risk Score Identifies Complications in CAR T-cell Therapy
This meta-analysis evaluates the CAR-HEMATOTOX score as a risk-stratification tool for patients receiving CAR T-cell therapy for hematologic…
A new scoring tool helps identify patients at higher risk for severe complications and infections during CAR T-cell therapy for blood cancer…
CAR T-cell therapies targeting specific antigens show potential for treating pediatric CNS tumors
New CAR T-cell therapies show promise for pediatric brain tumors
This narrative review synthesizes 18 studies, including preclinical and early-phase clinical trials, regarding CAR T-cell therapy for pediat…
CAR T-cell therapy is showing potential to shrink tumors and extend life in children with aggressive brain cancers like DIPG.
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Nanomedicine delivery systems may enhance immunotherapy efficacy in colorectal cancer
Nanomedicine may boost immunotherapy for colorectal cancer
This systematic review explores how nanomedicine delivery systems (liposomes, polymeric nanoparticles, metal nanoparticles) can remodel the …
Tiny particles could help immune therapies work better against colorectal cancer by changing the tumor environment.
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
Meta-analysis of CD38-directed CAR-T therapy in relapsed refractory multiple myeloma reports high response rates
New CD38 CAR-T therapy shows high success rates for late-stage multiple myeloma patients
This systematic review and meta-analysis evaluated CD38-directed CAR-T cell therapy in patients with relapsed refractory multiple myeloma.
A new immune therapy targeting CD38 and BCMA offers deep remission for late-stage multiple myeloma patients while managing side effects like…
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
All CAR T-cell therapy Articles
- Diverse expansion methods and automated platforms offer pathways to scalable CAR-T cell manufacturing
- CAR-T in solid tumors: 13% ORR, 63% DCR, lymphopenia most common AE
- CAR-T cell therapy shows preliminary clinical activity in refractory neuroimmune diseases
- B-cell targeted therapies show durable immune responses in pemphigus vulgaris and myasthenia gravis
- High CAR-HEMATOTOX scores correlate with increased ICAHT odds and worse survival in CAR T-cell therapy
- CAR T-cell therapies targeting specific antigens show potential for treating pediatric CNS tumors
- CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
- Nanomedicine delivery systems may enhance immunotherapy efficacy in colorectal cancer
- Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
- Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
- Meta-analysis of CD38-directed CAR-T therapy in relapsed refractory multiple myeloma reports high response rates
- CAR T-cell therapy linked to endocrine adverse events in FAERS analysis
- Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
- BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients